Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Network meta-analysis of global trials of 1L therapies in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.
Authors
Manish A. Shah
Weill Cornell Medical College, New York, NY
Manish A. Shah , Kohei Shitara , Sara Lonardi , Yee Chao , Kensei Yamaguchi , Bozena Kukielka-Budny , Min-Hee Ryu , Andrei Ungureanu , Mok Oh , Lawrence Chang , Hongbo Yang , Xinglei Chai , Pranob P. Bhattacharya , Maria Matsangou , Radhika Ranganath , Jaffer A. Ajani , Rui-Hua Xu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 325)
DOI
10.1200/JCO.2024.42.3_suppl.325
Abstract #
325
Poster Bd #
F5
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
STAR-221: A randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma.
First Author: Samuel J Klempner
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase 1b/2, open-label, dose-escalation and expansion trial of tucatinib in combination with trastuzumab with and without oxaliplatin-based chemotherapy or pembrolizumab in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in progress).
First Author: Haeseong Park
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Zolbetuximab + CAPOX versus CAPOX in first-line treatment of claudin18.2+/HER2– advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study.
First Author: Manish A. Shah
Poster
2021 Gastrointestinal Cancers Symposium
Pembrolizumab plus chemotherapy for previously untreated, HER2-negative unresectable or metastatic advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859.
First Author: Josep Tabernero